Wedbush Reduces Earnings Estimates for Revolution Medicines

by · The Cerbat Gem

Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) – Investment analysts at Wedbush decreased their FY2025 earnings estimates for Revolution Medicines in a research note issued to investors on Thursday, November 6th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($5.65) for the year, down from their prior estimate of ($5.14). Wedbush has a “Outperform” rating and a $80.00 price target on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.59) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.66) EPS, Q3 2026 earnings at ($1.70) EPS, Q4 2026 earnings at ($1.73) EPS, FY2026 earnings at ($6.73) EPS, FY2027 earnings at ($6.47) EPS, FY2028 earnings at ($4.56) EPS and FY2029 earnings at $0.32 EPS.

Several other analysts also recently issued reports on the company. National Bankshares set a $80.00 price objective on Revolution Medicines in a report on Friday, October 17th. Royal Bank Of Canada assumed coverage on shares of Revolution Medicines in a research report on Monday, November 3rd. They issued an “outperform” rating and a $77.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Wednesday, October 8th. The Goldman Sachs Group raised their price objective on shares of Revolution Medicines from $65.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Finally, HC Wainwright lifted their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Revolution Medicines has an average rating of “Buy” and a consensus price target of $78.71.

View Our Latest Research Report on Revolution Medicines

Revolution Medicines Stock Up 2.8%

Shares of Revolution Medicines stock opened at $62.73 on Monday. Revolution Medicines has a 12-month low of $29.17 and a 12-month high of $63.15. The firm has a market capitalization of $12.13 billion, a PE ratio of -12.13 and a beta of 1.25. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. The stock’s fifty day moving average is $49.12 and its 200-day moving average is $42.22.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period last year, the company earned ($0.94) earnings per share.

Hedge Funds Weigh In On Revolution Medicines

Several institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its stake in shares of Revolution Medicines by 8.9% during the 1st quarter. Wellington Management Group LLP now owns 11,787,921 shares of the company’s stock worth $416,821,000 after acquiring an additional 966,230 shares in the last quarter. Nextech Invest Ltd. lifted its holdings in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. BVF Inc. IL boosted its position in Revolution Medicines by 19.2% during the first quarter. BVF Inc. IL now owns 4,982,384 shares of the company’s stock worth $176,177,000 after purchasing an additional 801,205 shares during the period. Bellevue Group AG grew its holdings in Revolution Medicines by 4.7% during the second quarter. Bellevue Group AG now owns 4,579,300 shares of the company’s stock valued at $168,472,000 after purchasing an additional 205,000 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Revolution Medicines in the second quarter valued at approximately $62,584,000. 94.34% of the stock is currently owned by institutional investors.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, insider Lin Wei sold 2,160 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $45.82, for a total value of $98,971.20. Following the completion of the sale, the insider directly owned 88,339 shares of the company’s stock, valued at $4,047,692.98. The trade was a 2.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Margaret A. Horn sold 4,775 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $45.82, for a total transaction of $218,790.50. Following the transaction, the chief operating officer owned 145,900 shares in the company, valued at $6,685,138. This represents a 3.17% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 188,033 shares of company stock worth $8,456,208. 8.20% of the stock is currently owned by company insiders.

About Revolution Medicines

(Get Free Report)

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Featured Articles